The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis

Dai, Xiaoyu; Wang, Hongtao; Jing, Zhong; Fu, Ping

doi:10.1185/03007995.2014.921608

Cited by 14 publications

(8 citation statements)

References 40 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diabetics, metformin had shown to decrease HbA 1C , total and LDL cholesterol, serum triglycerides, fasting insulin levels and improves HDL cholesterol [ 35 – 37 ]. Metformin has shown to improve cardiovascular outcomes by mitigating apoptosis [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Singh

Bhansali

2016

BMC Dermatol

View full text Add to dashboard Cite

BackgroundIncreased prevalence of metabolic syndrome (MS) is observed in psoriasis. Metformin has shown improvement in cardiovascular risk factors while pioglitazone demonstrated anti proliferative, anti-inflammatory and anti angiogenic effects. Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS).MethodsSingle centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS.ResultsStatistically significant improvement was observed in Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores in pioglitazone (p values – PASI = 0.001, ESI = 0.002, PGA = 0.008) and metformin groups (p values – PASI = 0.001, ESI = 0.016, PGA = 0.012) as compared to placebo. There was statistically significant difference in percentage of patients achieving 75 % reduction in PASI and ESI scores in metformin (p value – PASI = 0.001, ESI = 0.001) and pioglitazone groups (p vaue – PASI = 0.001, ESI = 0.001). Significant improvement was observed in fasting plasma glucose (FPG) and triglycerides levels in metformin and pioglitazone arms. Significant improvement was noted in weight, BMI, waist circumference, FPG, triglycerides and total cholesterol after 12 weeks of treatment with metformin while pioglitazone showed improvement in FPG, triglyceride levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and LDL cholesterol levels. There was no difference in pattern of adverse drug reaction in three groups.ConclusionInsulin sensitizers have shown improvement in the parameters of MS as well as disease severity in psoriasis patients.Trial registrationCTRI Registration Number: CTRI/2011/12/002252. Registered on 19/12/2011.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Singh

Bhansali

2016

BMC Dermatol

View full text Add to dashboard Cite

show abstract

“…The only significant effect was obtained by the use of metformin on TG levels. Meta-analyses have shown positive although small effect of metformin on lipid profile factors in diabetic patients [ 33 ], while combination of metformin with other noninsulin anti-hyperglycemic drugs was found to be moderate to small [ 34 ]. In NAFLD patients, as well as obese non-diabetic patients various results had been obtained, with effectiveness of metformin shown in some cases [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Cymene and Metformin treatment effect on biochemical parameters of male NMRI mice fed with high fat diet

Lotfi

Yaghmaei

Ebrahim‐Habibi

2015

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundThe increasing prevalence of obesity is considered a serious global health threat. Mainly due to change of diet and reduced physical activity, obesity is an important risk factor for chronic diseases. A higher level of cytokines and a general inflammatory state has also been associated with this condition. With this regard, potential anti-obesity compounds with anti-inflammatory properties could be beneficial in better control of the disease. p-Cymene is a natural aromatic compound that has been shown to have anti-inflammatory properties, while the antidiabetic drug metformin has been observed to be effective as an aid for weight loss. In this study, the effect of these comounds was compared in a high fat diet treated mice model.Methods48 adult NMRI mice were randomly divided into six groups: control group receiving a normal diet, high fat diet (HFD) fed control group, sham group receiving HFD and sunflower seed oil, Experimental group1 (E1) receiving HFD and 20 mg/kg metformin, Experimental group2 (E2) receiving 20 mg/kg metformin and 20 mg/kg p-cymene, Experimental group3 (E3) receiving 20 mg/kg p-cymene. Compounds were administered by intragastric gavage for 45 days.ResultsNon-fasting glucose serum levels, ALT, and ALP of E2 and E3 decreased significantly compared to HFD control group. In the E3 group, AST levels decrease was also significant. In E1, non-fasting glucose and TG serum levels decreased significantly compared to HFD control group. Histological observations on liver tissue showed an increase of lipid droplets in the HFD control group compared with the normal group, while upon treatment with the compounds, lipid droplets decreased and the cells appeared to be more ordered.Conclusionp-Cymene has a potential to ameliorate biochemical parameters in high fat diet treated mice, and its concurrent use with metformin was effective.

show abstract

“…Several recent meta-analyses indicated modest reductions in fasting LDL-C, total cholesterol, and TG with small or no significant improvement in HDL-C following chronic treatments with GLP-1R agonists (12)(13)(14) or DPP-4 inhibitors (13,15). For example, treatment with exenatide or liraglutide for several weeks to 3 years reduced fasting levels of TG, total cholesterol and LDL-C, increased HDL-C (16)(17)(18)(19); and reduced fasting apoB (19)(20)(21)(22), apoB-48 (a surrogate measure of intestinal lipoprotein particle numbers) (23), and free fatty acid (FFA) (24)(25)(26).…”

Section: Glp-1r Agonists Improve Fasting and Postprandial Lipid Profimentioning

confidence: 99%

Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

et al. 2015

View full text Add to dashboard Cite

Individuals with metabolic syndrome and frank type 2 diabetes are at increased risk of atherosclerotic cardiovascular disease, partially due to the presence of lipid and lipoprotein abnormalities. In these conditions, the liver and intestine overproduce lipoprotein particles, exacerbating the hyperlipidemia of fasting and postprandial states. Incretin-based, antidiabetes therapies (i.e., glucagon-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy for the treatment of hyperglycemia. Evidence is accumulating that these agents also improve fasting and postprandial lipemia, the latter more significantly than the former. In contrast, the gut-derived peptide GLP-2, cosecreted from intestinal L cells with GLP-1, has recently been demonstrated to enhance intestinal lipoprotein release. Understanding the roles of these emerging regulators of intestinal lipoprotein secretion may offer new insights into the regulation of intestinal lipoprotein assembly and secretion and provide new opportunities for devising novel strategies to attenuate hyperlipidemia, with the potential for cardiovascular disease reduction.

show abstract

The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis

Cited by 14 publications

References 40 publications

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Cymene and Metformin treatment effect on biochemical parameters of male NMRI mice fed with high fat diet

Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

Contact Info

Product

Resources

About